Acasti Pharma Share Holder Equity 2014-2024 | GRCE

Acasti Pharma share holder equity from 2014 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Acasti Pharma Annual Share Holder Equity
(Millions of US $)
2024 $62
2023 $68
2022 $108
2021 $56
2020 $13
2019 $11
2018 $6
2017 $17
2016 $21
2015 $21
2015 $
2014 $32
2014 $
2013 $10
2013 $
Acasti Pharma Quarterly Share Holder Equity
(Millions of US $)
2024-06-30 $59
2024-03-31 $62
2023-12-31 $65
2023-09-30 $67
2023-06-30 $64
2023-03-31 $68
2022-12-31 $97
2022-09-30 $100
2022-06-30 $104
2022-03-31 $108
2021-12-31 $111
2021-09-30 $114
2021-06-30 $53
2021-03-31 $56
2020-12-31 $26
2020-09-30 $9
2020-06-30 $11
2020-03-31 $13
2019-12-31 $-5
2019-09-30 $-1
2019-06-30 $3
2019-03-31 $11
2018-12-31 $23
2018-09-30 $-11
2018-06-30 $6
2018-03-31 $6
2017-12-31 $12
2017-09-30 $12
2017-06-30 $14
2017-02-28 $17
2016-11-30 $15
2016-08-31 $17
2016-05-31 $19
2016-03-31 $19
2016-02-29
2015-12-31 $22
2015-09-30 $24
2015-06-30 $26
2015-03-31 $30
2014-12-31 $32
2014-09-30 $30
2014-06-30 $32
2014-03-31 $32
2014-02-28
2013-12-31 $20
2013-09-30 $21
2013-06-30 $8
2013-03-31 $10
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00